Biosfer Teslab
Biosfer Teslab is a Spanish medical software spin-off that develops NMR-based metabolomics diagnostic tests, including the Liposcale lipoprotein test for cardiovascular risk and the MetBalance consumer metabolic health test, serving clinicians, researchers, and pharma.
- Company typePrivate
- Founded2013
- HeadquartersReus, Spain
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Biosfer Teslab does
Biosfer Teslab is a privately-held Spanish medical software company, founded in December 2013 as a spin-off of the Universitat Rovira i Virgili (URV) and the Institut d'Investigació Sanitària Pere Virgili (IISPV), headquartered in Reus, Tarragona. The company develops proprietary in vitro diagnostic software and analytical services based on 1H-NMR (proton Nuclear Magnetic Resonance) spectroscopy, applying machine learning and artificial intelligence to derive lipoprotein profiles, glycoprotein signatures (GlycA/GlycB), lipidomic families, and low molecular weight metabolite data from blood and biological samples.
The company's commercial portfolio is anchored by two core products: the Liposcale Test, an advanced lipoprotein profiling test launched in 2020 for cardiovascular risk stratification in clinical settings, and the MetBalance Test, a direct-to-consumer metabolic health assessment launched in 2022 that translates NMR metabolomic data into personalized health visualizations. Complementary revenue comes from fee-for-service Metabolomic Services (lipoprotein profiling, glycoprotein analysis, aqueous metabolome, lipidomic families) provided to universities, research centers, and pharmaceutical companies globally, plus Data Science Services that interpret complex biological data using ML/AI for institutional clients.
Biosfer Teslab operates a sales-led go-to-market with direct B2B engagement of clinicians, cardiologists, lipidologists, and clinical laboratories in Spain, supported by ICEX Next for international expansion, plus direct-to-consumer e-commerce for the MetBalance Test. The company has analyzed over 30,000 samples and produced 100+ peer-reviewed scientific publications. R&D is substantially grant-funded through Spanish public institutions (CDTI, AGAUR, ENISA, ACCIÓ, Ministerio de Ciencia) and European programs (Horizon 2020, Horizon Europe, COST, NextGenerationEU), with a team size of 11–50 employees. Certifications include ISO 13485:2016, ISO 9001:2015, GDPR compliance, AEMPS software development license, and certified innovative SME status.
Biosfer Teslab firmographics
Firmographics- Name
- Biosfer Teslab
- Legal name
- BIOSFER TESLAB, SL
- Website
- https://biosferteslab.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biosfer Teslab is a Spanish medical software spin-off that develops NMR-based metabolomics diagnostic tests, including the Liposcale lipoprotein test for cardiovascular risk and the MetBalance consumer metabolic health test, serving clinicians, researchers, and pharma.
- Ownership category
- akta.pro rank
Biosfer Teslab industry classification
Industry- Product category
- Clinical Diagnostics Software
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Metabolomics & Lipidomics Services (HLAGANAG)
- akta.pro secondary industries
- Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Biosfer Teslab is headquartered
LocationHeadquarters
- HQ city
- Reus
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Biosfer Teslab business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Liposcale Test Services: Provides advanced cardiovascular risk stratification lipoprotein testing services to health professionals and clinical laboratories on a fee-per-test basis, including direct-to-professional clinical testing.
- Metabolomic Research Services: Offers metabolomic analysis services to universities, research centers, and pharmaceutical companies on a project or fee-per-sample basis, supporting biomarker discovery and clinical research.
- MetBalance Test (Direct-to-Consumer): Consumer-facing metabolic health assessment product available through metbalancetest.com, translating NMR metabolomic data into personalized health insights.
- Data Science Services: Provides specialized data analysis and interpretation of complex biological data to support research and clinical decision-making for institutional clients.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Biosfer Teslab product offering
Product offeringCore offering
Biosfer Teslab develops and provides medical software and IT tools based on Nuclear Magnetic Resonance (NMR) spectroscopy for the analysis of fluids and biological tissues. The company sells the Liposcale Test for advanced cardiovascular risk stratification through lipoprotein profiling, the MetBalance Test for personalized consumer metabolic health monitoring, NMR-based metabolomic research services, and data science services for biological data interpretation, all powered by proprietary computational methods and AI/ML.
Product overview
Biosfer Teslab operates as a spin-off of the University Rovira i Virgili and Institut d'Investigació Sanitària Pere Virgili, providing NMR-based diagnostic services and products. The portfolio centers on the Liposcale Test for advanced cardiovascular risk assessment through lipoprotein analysis, complemented by the MetBalance Test for personalized metabolic health monitoring. The company offers Metabolomic Services for research applications and Data Science Services for biological data interpretation. All products leverage Nuclear Magnetic Resonance (NMR) spectroscopy technology combined with AI and machine learning for precision medicine applications.
Differentiator
Problem solved
Functional benefit
Brands
- Liposcale: Advanced lipoprotein test for cardiovascular risk stratification using NMR spectroscopy, providing comprehensive characterization of lipoprotein profile including lipid content, particle number, and size.
- MetBalance Test
Products and services
- Liposcale Test Advanced lipoprotein testing using 1H-NMR spectroscopy that provides comprehensive characterization of lipoprotein profiles including particle number, size, and lipid content for cardiovascular risk stratification. Identifies atherogenic small TG-rich remnant lipoproteins, small LDL particles, remnant cholesterol, and TG enrichment in HDL. Targeted at health professionals including cardiologists, endocrinologists, lipid specialists, and general practitioners for patient cardiovascular risk assessment and dyslipidemia management.
- MetBalance Test Comprehensive metabolic health assessment tool that translates NMR-based blood analysis, artificial intelligence, and data visualization into personalized metabolic state evaluation, generating metabolic age images and health status visualizations. Targeted at health-conscious individual consumers for personal metabolic health monitoring, wellness optimization, and metabolic age tracking via metbalancetest.com.
- Metabolomic Services Research analytical services providing NMR-based metabolomics analysis including advanced lipoprotein profiling, glycoprotein characterization (GlycA and GlycB), aqueous plasma metabolome (LMWM), and lipid family analysis for biomedical and clinical research. Targeted at academic research groups at universities, research centers, and pharmaceutical/biotech companies for biomarker discovery, clinical studies, epidemiological investigations, and multi-omic integration projects.
- Data Science Services Analytical and interpretive services for complex biological data supporting research and clinical decision-making through advanced computational analysis and machine learning approaches. Targeted at institutional clients including research institutions and pharmaceutical companies needing support for biomarker discovery and clinical research data interpretation.
Quantifiable outcome
- Detection of increased atherogenic small TG-rich remnant lipoproteins and small LDL particles that are not identifiable through standard lipid measures
- +3 more outcomes
Companies that use Biosfer Teslab
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Biosfer Teslab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Biosfer Teslab partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- AM BIOTAcoreBiosfer Teslab and AM BIOTA announced a unique collaboration to develop a personalized medicine test combining metabolomics and microbiota analysis for improved patient stratification and health management.
- Laboratorios RubiócoreLaboratorios Rubió, a family company specializing in therapeutic solutions for low-prevalence diseases, co-developed a pioneering cardiovascular prediction test in Europe with Biosfer Teslab, planned for launch across the European market.
- Universitat Rovira i Virgili (URV)coreBiosfer Teslab is a spin-off company of the Rovira i Virgili University (URV), originating from the university's research environment. The company maintains close ties with URV's research groups and benefits from academic collaboration, talent pipeline, and research infrastructure.
- Institut d'Investigació Sanitària Pere Virgili (IISPV)coreBiosfer Teslab is a spin-off of the Institut d'Investigació Sanitària Pere Virgili (IISPV), collaborating closely with IISPV's metabolomics platform led by Dr. Xavier Correig. The company co-participates in research projects including the VISIONING COVID-19 project as CO-IP with Dr. Correig.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Biosfer Teslab competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: International testing laboratory group operating across clinical diagnostics, pharma services, and metabolomics-adjacent analytical services. Broad incumbent with overlapping metabolomics, biomarker, and clinical testing capabilities relevant to Biosfer's research services business.
- Bruker Corporation: Manufacturer of NMR spectrometers and mass spectrometry instruments used in metabolomics research and clinical labs. Relevant as both a potential instrument supplier and an adjacent player expanding into clinical NMR applications, including partnerships with diagnostic developers.
- Labcorp: Global clinical diagnostics leader that acquired LipoScience (pioneer of NMR lipoprotein analysis). Represents the broad incumbent that has already consolidated the NMR lipoprotein subcategory, posing both a competitive threat and a potential partner/acquirer for Biosfer's Liposcale technology.
- Quest Diagnostics: Largest US clinical laboratory network offering advanced cardiovascular and metabolic testing. Represents the broad incumbent benchmark for advanced lipid and metabolic risk testing commercial scale, against which Biosfer's Liposcale must differentiate to gain clinical adoption.
Emerging players
- Olink Holding: Swedish proteomics company providing high-multiplex biomarker discovery and clinical validation services to pharma and academic researchers. Comparable as a European specialty omics platform serving the same pharma biomarker discovery and clinical research customer segments targeted by Biosfer's research services.
- C2N Diagnostics: Specialty diagnostics company developing blood-based biomarker tests for neurodegenerative disease using mass spectrometry and proteomics. Comparable as a focused clinical diagnostics innovator translating advanced analytical technologies into clinical biomarker products, though in a different disease area.
Direct peers
- Metabolon: US-based metabolomics services provider offering untargeted metabolomics profiling and lipidomics for pharma, academic, and consumer health clients. Directly competes with Biosfer Teslab's Metabolomic Research Services in biomarker discovery and pharma research support.
- Nightingale Health: Finnish company providing NMR-based metabolomic profiling and cardiovascular risk biomarkers at scale. Directly comparable as the leading commercial NMR metabolomics platform targeting clinical cardiovascular risk and research applications, with analogous biomarker products (e.g., Nightingale's circulating metabolic biomarkers vs. Biosfer's Liposcale).
- Bevital: Norwegian specialized metabolomics laboratory offering NMR- and LC-MS-based biomarker analyses for epidemiological and clinical research. Closely comparable niche metabolomics services provider serving research institutions and pharma, similar in scale and academic origin to Biosfer Teslab.
Regional players
- Synlab: European medical diagnostics services provider with strong presence across continental Europe. Comparable as a regional clinical diagnostics services network that could distribute or adopt NMR-based cardiovascular tests like Liposcale within its pan-European laboratory footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Biosfer Teslab social profiles
Digital presenceBiosfer Teslab compliance and trust
Trust signalCompliance5 records
Biosfer Teslab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biosfer Teslab leadership team
Management profileNumber of profiles
Profiles9 records
Biosfer Teslab funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biosfer Teslab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biosfer Teslab
What does Biosfer Teslab do?
Biosfer Teslab develops and provides medical software and IT tools based on Nuclear Magnetic Resonance (NMR) spectroscopy for the analysis of fluids and biological tissues. The company sells the Liposcale Test for advanced cardiovascular risk stratification through lipoprotein profiling, the MetBalance Test for personalized consumer metabolic health monitoring, NMR-based metabolomic research services, and data science services for biological data interpretation, all powered by proprietary computational methods and AI/ML.
Is Biosfer Teslab a public or private company?
Biosfer Teslab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Biosfer Teslab founded?
Biosfer Teslab was founded in 2013. It employs 11 to 50 people.
Where is Biosfer Teslab based?
Biosfer Teslab is headquartered in Reus, Spain, in the Europe region.
How does Biosfer Teslab make money?
Four revenue lines are on record. Liposcale Test Services are the primary driver. The others are metabolomic Research Services, metBalance Test (Direct-to-Consumer) and data Science Services.
Who are Biosfer Teslab's main competitors?
Broad incumbents on record are Eurofins Scientific, Bruker Corporation, Labcorp and Quest Diagnostics. Emerging players are Olink Holding and C2N Diagnostics. Direct peers are Metabolon, Nightingale Health and Bevital. Synlab is listed as a regional player.
Does Biosfer Teslab have an API?
No public API is recorded for Biosfer Teslab.
What industry is Biosfer Teslab in?
Biosfer Teslab's product category is Clinical Diagnostics Software. Its primary akta.pro industry code is HLAGANAG, Metabolomics & Lipidomics Services, with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.